| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,763,340 | 1,800,057.5* | 2,849,510 | 2,758,973 |
| General and administrative | 2,590,205 | 2,097,690* | 1,936,267 | 2,330,553 |
| Total operating expenses | 5,353,545 | 3,897,747.5 | 4,785,777 | 5,089,526 |
| Loss from operations | -5,353,545 | -3,897,747.5* | -4,785,777 | -5,089,526 |
| Interest income, net | 93,052 | 63,431* | 78,074 | 42,568 |
| Foreign exchange gain, net | -165,173 | 138,786* | -27,382 | -620,924 |
| Loss before income tax | -5,425,666 | -3,695,530.5* | -4,735,085 | -5,667,882 |
| Income tax | 183,066 | -174,621.5* | 549,288 | 141,205 |
| Net loss | -5,608,732 | -3,520,909 | -5,284,373 | -5,809,087 |
| Basic EPS | -0.13 | -0.105 | -0.15 | -0.19 |
| Diluted EPS | -0.13 | -0.105 | -0.15 | -0.19 |
| Basic Average Shares | 42,230,248 | 33,565,425 | 34,998,060 | 30,341,523 |
| Diluted Average Shares | 42,230,248 | 33,565,425 | 34,998,060 | 30,341,523 |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)